Results of a safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers

被引：4

作者：

Proulx, L. ^{[1
]}

Bourgault, B. ^{[1
]}

Chauret, N. ^{[1
]}

Larouche, R. ^{[2
]}

Tanguay, M. ^{[2
]}

Thibert, R. ^{[1
]}

机构：

[1] ViroChem Pharma Inc, Laval, PQ, Canada

[2] Anapharm A PharmaNet Co, Montreal, PQ, Canada

来源：

JOURNAL OF HEPATOLOGY | 2008年 / 48卷

关键词：

D O I：

10.1016/S0168-8278(08)60856-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

854

引用

页码：S320 / S321

页数：2

共 50 条

[41] A tolerability, safety and pharmacokinetic study of single and multiple oral doses of novel D3 partial agonist RGH-790 in healthy male volunteers
Nagy, K.
Laszlovszky, I.
Markus, Z.
Nemeth, G.
Magyar, G.
Juhasz, Z.
Kapas, M.
Szombathelyi, Z.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S208 - S208
[42] A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor
Dennie, Justin
Vandell, Alexander G.
Inoue, Satoshi
Gajee, Roohi
Pav, Joseph
Zhang, George
Zamora, Cynthia
Masuda, Nobuhisa
Uchiyama, Minoru
Yamada, Makiko
Senaldi, Giorgio
JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1557 - 1565
[43] Safety, Tolerability and Pharmacokinetics of Trimebutine 3-Thiocarbamoylbenzenesulfonate (GIC-1001) in a Randomized Phase I Integrated Design Study: Single and Multiple Ascending Doses and Effect of Food in Healthy Volunteers
Paquette, Jean-Michel
Rufiange, Marianne
Niculita, Mirela Iovu
Massicotte, Julie
Lefebvre, Marc
Colin, Patrick
Telmat, Ariles
Ranger, Maxime
CLINICAL THERAPEUTICS, 2014, 36 (11) : 1650 - 1664
[44] Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults
Kakuda, Thomas N.
Yogaratnam, Jeysen
Rito, Jennifer
Boyce, Malcolm
Mitchell, Toni
Gupta, Kusum
Symons, Julian A.
Chanda, Sushmita
Van Remoortere, Pieter
Fry, John
ANTIVIRAL THERAPY, 2018, 23 (07) : 555 - 566
[45] Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA-8010 in healthy subjects: First-in-human phase I study
Lee, Dae Young
Lee, Min Jung
Ryu, Chaelim
Lee, Heewon
Brooks, Ashley
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (01):
[46] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RG1678, A NOVEL GLYCINE REUPTAKE INHIBITOR: A MULTIPLE ASCENDING DOSE STUDY IN HEALTHY VOLUNTEERS.
Boetsch, C.
Hofmann, C.
Martin-Facklam, M.
Banken, L.
Biedinger, U.
Patat, A.
Boutouyrie, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S57 - S57
[47] Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women
Lammerich, Andreas
Bias, Peter
Gertz, Beate
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 707 - 715
[48] A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers
Trucksis, Michele
Friedman, Evan
Taylor, Adekemi
Delgado, Liliana
Reynders, Tom
DeSmet, Marina
Dong, Yingwen
Fu, Irong
DeMeyer, Igance
Chodakewitz, Jeffrey
Iwamoto, Marian
Wagner, John
CANCER RESEARCH, 2009, 69
[49] A phase I safety, pharmacokinetic, and pharmacodynamic study of ascending single, oral doses of ICA-17043, a novel Gardos channel inhibitor for the treatment of Sickle Cell Disease.
Rigdon, G
Stocker, J
McNaughton-Smith, G
Hull, H
Leese, P
BLOOD, 2000, 96 (11) : 20B - 21B
[50] Safety, tolerability and pharmacokinetics of R1626, a novel nucleoside analog targeting hcv polymerase: Results from a phase I single dose escalation trial in healthy subjects.
Robson, R.
Berns, H.
Brand, M.
Feltner, S.
Hill, G.
Ipe, D.
Love, J.
Mannino, M.
O'Mara, E.
Tu, Y.
Washington, C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S98 - S98

← 1 2 3 4 5 →